Initiator Pharma (INIT) Life Science Summit 2025 summary

Pipeline and clinical focus

• Advancing clinical drugs for sexual dysfunctions and pain, targeting monoamines in the brain.

• Pudofencin is being developed for organic erectile dysfunction and vulvodynia, with phase II data in ED and phase I pain challenge data.

• Pre-clinical and clinical data show efficacy in neuropathic pain and female sexual dysfunction.

• Vulvodynia affects over 30 million women in the US and Europe, with no approved therapies currently available.

• Pudofencin targets central pain sensitization, aiming to provide first-in-class relief for vulvodynia.

Clinical trial design and execution

• Approved randomized, double-blind, placebo-controlled crossover study in 24 women with vulvodynia.

• Primary endpoint is pain threshold measured by Wagner Algometer; secondary endpoint is tampon test.

• Study includes follow-up on pain relief duration and impact on daily activities.

• Patient enrollment is ongoing, with study costs covered by a CRO investing at a 40% premium, converting costs to shares.

• Financing secured through 2027, with trial readout expected by end of 2026.

Market opportunity and business development

• Vulvodynia market estimated at over EUR 3.5 billion in peak sales with 10% penetration.

• Pricing assumptions are conservative, with US pricing below current hot flash medications.

• First-mover advantage expected in a market with no approved treatments.

• Active dialogues with companies in women's health, with phase II efficacy data seen as key for partnerships.

• Focus on regional or global partnerships, leveraging strong patent protection and non-opioid profile.